Skip to content
Aminoscope
Head-to-head

Exenatide vs Liraglutide

The first GLP-1 ever approved against the one that displaced it. DURATION-6 compared them directly, and the result was not close.

By Julian RothResearch & dataUpdated October 2026

Short answer

Exenatide and liraglutide are both FDA-approved drugs, but they are aimed at different problems. For a reader focused on type 2 diabetes, exenatide is the relevant choice; liraglutide is marketed for obesity and type 2 diabetes. The headline human result for exenatide is HbA1c about 0.8 percentage points lower than placebo over 30 weeks when added to metformin.

Exenatide

Byetta / Bydureon

FDA-approved

The first GLP-1 to market (a synthetic Gila-monster exendin-4) — approved for diabetes with a neutral CV outcome (EXSCEL); a modest weight effect, now superseded by weekly semaglutide/tirzepatide.

Full Exenatide evidence review

Liraglutide

Saxenda / Victoza

FDA-approved

The first-gen daily GLP-1: ~8% weight loss in SCALE plus a proven CV benefit (LEADER) — real, but modest and now eclipsed by weekly semaglutide and tirzepatide.

Full Liraglutide evidence review

Exenatide vs Liraglutide: head to head

FDA status / approved use

Exenatide

FDA-approved in 2005 for type 2 diabetes (Byetta, Bydureon); never approved for weight loss

Liraglutide

Approved as Victoza for type 2 diabetes (2010) and Saxenda for weight management (2014); prescription only
Marketed for

Exenatide

Type-2 diabetes

Liraglutide

Obesity, type-2 diabetes
Outcome areas

Exenatide

Blood sugar / insulin sensitivity

Liraglutide

Weight loss / appetite; Blood sugar / insulin sensitivity; Cardiovascular
Evidence grade

Exenatide

FDA-approved

Liraglutide

FDA-approved
How it works

Exenatide

Synthetic copy of exendin-4 that mimics GLP-1 but resists breakdown by DPP-4

Liraglutide

First-generation GLP-1 receptor agonist lasting long enough for once-daily dosing
Route and dosing

Exenatide

Subcutaneous injection, twice daily (Byetta) or once weekly (Bydureon)

Liraglutide

Subcutaneous injection, once daily
Headline human result

Exenatide

HbA1c about 0.8 percentage points lower than placebo over 30 weeks when added to metformin

Liraglutide

About 8% mean body-weight loss vs about 2.6% on placebo at 56 weeks in the SCALE trial
Strongest evidence

Liraglutide

SCALE Obesity, NEJM 2015Liraglutide evidence reviewPubMed 26132939
Key safety signal

Exenatide

Nausea is the dominant side effect; the weekly form adds injection-site nodules

Liraglutide

Gastrointestinal side effects including nausea, vomiting, diarrhea and constipation
How it is obtained

Exenatide

Prescription drug

Liraglutide

Prescription drug

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

FDA-approved:
Approved by the FDA for a defined indication, on the strength of pivotal human trials.

Our verdict

In DURATION-6, once-daily liraglutide 1.8 mg beat once-weekly exenatide on both HbA1c (a reduction of about 1.48% versus 1.28%) and weight (roughly 3.6 kg versus 2.7 kg). The outcomes data point the same way: liraglutide cut major adverse cardiovascular events by about 13% in LEADER, while exenatide was safe in EXSCEL but showed no statistically significant reduction. Both are approved for type 2 diabetes; only liraglutide is also approved for chronic weight management. Exenatide's significance today is mostly historical.

Exenatide fits if

You have a specific reason to stay on exenatide, such as availability or an established individual response, and glucose control is the goal.

Liraglutide fits if

You want the stronger of the two on glucose, weight, and cardiovascular outcomes, and can accept a daily injection.

Exenatide vs Liraglutide: common questions

Are exenatide and liraglutide both FDA-approved?
Yes. Exenatide was FDA-approved in 2005 for type 2 diabetes (Byetta, Bydureon); never approved for weight loss. Liraglutide is approved as Victoza for type 2 diabetes (2010) and Saxenda for weight management (2014); prescription only.
Which has stronger human evidence, exenatide or liraglutide?
Neither clearly. Both have approval-level evidence. The key source for exenatide is EXSCEL, NEJM 2017; for liraglutide, it is SCALE Obesity, NEJM 2015.
What are the main safety concerns with exenatide and liraglutide?
With exenatide, nausea is the dominant side effect; the weekly form adds injection-site nodules. For liraglutide, watch for gastrointestinal side effects including nausea, vomiting, diarrhea and constipation.

Key studies behind each

Exenatide

  1. Eng J, Kleinman WA, Singh L, et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. PubMed 1313797
  2. DeFronzo RA, Ratner RE, Han J, et al. (2005). Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. PubMed 15855572
  3. Drucker DJ, Buse JB, Taylor K, et al. (2008). Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (DURATION-1). Lancet. PubMed 18782641
  4. Buse JB, Nauck M, Forst T, et al. (2013). Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. PubMed 23141817

Liraglutide

  1. Pi-Sunyer X, Astrup A, Fujioka K, et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. PubMed 26132939
  2. Marso SP, Daniels GH, Brown-Frandsen K, et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. PubMed 27295427
  3. Capehorn MS, Catarig AM, Furberg JK, et al. (2020). Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. PubMed 31539622
  4. Kelly AS, Auerbach P, Barrientos-Perez M, et al. (2020). A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity (SCALE Teens). N Engl J Med. PubMed 32233338

The full evidence reviews

Related comparisons